Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas

Modern Pathology

Volumn 12, Issue 11, 1999, Pages 1001-1009

  Rao, Uma N M ^a   Finkelstein, Sydney D ^a   Jones, Merka W ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

CD44s; Estrogen receptor; Glut1; Mdm2; Microdissection; P53

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MALE; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

ADULT; AGED; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASM PROTEINS; UTERINE NEOPLASMS;

EID: 0032756873     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Enzinger FM, Weiss SW. Soft tissue tumors. 3rd ed. St. Louis: Mosby; 1995. p. 467-510.
2. Tiltman AJ. Smooth muscle neoplasms of the uterus. Curr Opin Obstet Gynecol 1997;9:48-51.
3. Hall KL, Teneriello MG, Taylor RR, Lemon S, Ebina M, Linnoila RI, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol 1997;65:330-5.
4. Niemann TH, Raab SS, Lenel JC, Rodgers JR, Robinson RA. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 1995;26:375-9.
5. Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994;69:1052-8.
6. O'Reilly PE, Raab SS, Niemann TH, Rodgers JR, Robinson RA. p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. Mod Pathol 1997;10: 91-7.
7. Hill MA, Gong C, Casey TJ, Menon AG, Mera R, Gillespie AT, et al. Detection of K-ras mutations in resected primary leiomyosarcoma. Cancer Epidemiol Biomarkers Prev 1997;6: 1095-100.
8. Akwari OE, Dozois RR, Weiland L, Beahrs OH. Leiomyosarcoma of small and large bowel. Cancer 1978;42:1375-84.
9. Ranchod M, Kempson RL. Smooth muscle tumors of gastrointestinal tract and retroperitoneum. Cancer 1977;39:235-62.
10. Gustafson P, Willen H, Baldertorp B, et al. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer 1992;70:114-9.
11. Fox H, editor. Haines and Taylor obstetrical and gynecological pathology. 4th ed. Churchill Livingstone; 1995. Vol 1. pp. 519-586.
12. Robboy SJ, Mehta K, Norris HJ. Malignant potential and pathology of leiomyomatous tumors of the uterus. Clin Consult Obstet Gynecol 1990;2:2-9.
13. Principles and Practice of Surgical Pathology and Cytopathology. 3rd ed. In: Silverberg SG, editor. Neoplastic diseases of small and large intestine. Churchill Livingstone; 1997. p. 1835-65.
14. Emory TS, Sobin LH, Lukes L, Lee DH, Leary TJ. Prognosis of gastrointestinal smooth muscle tumors. Dependence on anatomic site. Am J Surg Pathol 1999;23:82-7.
15. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
16. Younes M, Lechago LV, Somoano JR, Moshraf M, Lechago J. Wide expression of human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 1996;56:1164-7.
17. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997;50:57-71.
18. Finkelstein SD, Przygodzki RM, Pricolo VE, Sakallah SA, Swalsky PA, Bakker A, et al. Prediction of biological aggressiveness in colorectal cancer by p53/k-ras-2 topographic genotyping: concepts for molecular testing. Mol Diagn 1996;1:5-28.
19. Finkelstein SD, Przygodzki R, Swalsky PA. Microdissection-based p53 genotyping: concepts for molecular testing. Mol Diagn 1998;3:179-91.
20. Hahn M, Fislage R, Pingoud A. Polymorphism of the pentanucleotide repeat d (AAAAT) within intron 1 of the human tumor suppressor gene p53 (17p13.1). Hum Genet 1995;95: 471-2.
21. Holst VA, Finkelstein SD, Yousem SA. Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol 1998;22:1343-50.
22. Finkelstein SD, Sasyegh R, Christensen S, Swalsky P. Genotypic classification of colorectal adenocarcinoma correlates with biological behavior. Cancer 1993;71:3827-38.
23. Heighway J, Mitchell EL, Jones D, White GR, Santibanez Koref MF. A transcribed polymorphism and sub-localisation of MDM2. Hum Genet 1994;93:611-2.
24. Fujii S, Nakashima N, Okamura H, et al. Progesterone-induced smooth muscle-like cells in the subperitoneal nodules produced by estrogen. Experimental approach to leiomyomatosis peritonealis disseminata. Am J Obstet Gynecol 1981;139:164-72.
25. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways [review]. Biol Reprod 1998;58:627-32.
26. Vu K, Greenspan DL, Wu TC, Zacur HA, Kurman RJ. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29:359-63.
27. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Am J Gynecol Pathol 1999;18:20-8.
28. Lessl M, Klotzbuecher M, Schoen S, Reles A, Stockemann K, Fuhrmann U. Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. J Clin Endocrinol Metab 1997;82:2596-600.
29. Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, et al. Molecular biology of mammalian glucose transporters. Diabetes Care 1990;13:198-208.
30. Ismail-Beigi F. Metabolic regulation of glucose transport. J Membr Biol 1993;135:1-10.
31. Burstein DE, Reder I, Weiser K, Tong T, Pritsker A, Haber RS. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol 1998;11: 392-6.
32. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage 1 nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
33. Younes M, Brown RW, Mody DR, Fernandez L, Laucerica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15: 2895-8.
34. Boado JR, Black KL, Pardrige WM. Gene expression of GLUT1 and GLUT 3 glucose transporters in human brain tumors. Mol Brain Res 1994;27:51-7.
35. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993;5:667-75.
36. Ghoshen R, Areil I, Shuster S, Hochberg A, Voldavsky I, De Groot N, et al. Hyaluronan, CD44 and its variant exons in human trophoblastic invasion and placental angiogenesis. Mol Hum Reprod 1996;9:685-91.
37. Adams JM, Cory S. The Bcl2 protein family: arbiters of cell survival [review]. Science 1997;281:1322-6.
38. Nakanishi H, Oshawa M, Naka N, Uchida A, Ochi T, Aozasa K. Immunohistochemical detection of bcl2 and p53 proteins and apoptosis in soft tissue sarcomas: their correlation with prognosis. Oncology 1997;54:238-44.
39. Jensen V, Sorensen FB, Bentzen SM, Ladekarl M, Nielson OS, Keller J, et al. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 1998;32:536-46.
40. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T, Aozasa K. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 1997;54:238-44.
41. Suster S, Fisher C, Moran CA. Expression of bcl2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces and gastrointestinal tract. Am J Surg Pathol 1998;22:863-72.
42. Gillet C, Smith P, Gregory W, Richards M, Mills R, Peters G, et al. Cyclin D1 and prognosis in breast cancer. Int J Cancer 1996;69:92-9.
43. Maelandsmo GM, Berner J-M, Florenens VA, Forus A, Hovig E, Fodstad O, et al. Homozygos deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1997;72:1095-100.
44. Welcker M, Lukas J, Strauss M, Bartek J. Enhanced protein stability: a novel mechanism of D-type overabundance identified in human sarcoma. Oncogene 1996;13:419-25.
45. Jeffers MD, Farquharson MA, Richmond JA, McNicol AM. p53 immunoreactivity and mutations of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 1995; 177:65-70.
46. Dei Tos AP, Maestro R, Doglioni C, Piccinin S, Libera DD, Boiocchi M, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996;148:1037-45.
47. Wurl P, Meye A, Schmidt H, Lautenschlager C, Kalthoff H, Rath FW, et al. High prognostic significance of Mdm2/p53 co-expression in soft tissue sarcomas of the extremities. Oncogene 1998;16:1183-5.
48. Wurl P, Meye A, Berger D, Bache M, Lautenschlager C, Schmidt H, et al. Prognostic significance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas. Diagn Mol Pathol 1997;6:249-54.
49. Blom R, Guerreri C, Stal O, Malstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm2 analysis of 49 cases. Gynecol Oncol 1998;68:54-61.